Log Out


The promise of PACAP 

Despite recent advances in preventive therapy for migraine, unmet medical needs remain for a significant proportion of patients and research into emerging targets for molecular therapy continue.  At EHF 2018, we heard from Anne Vollesen (Danish Headache Centre, Denmark), who provided a review of pituitary adenylate-cyclase-activating polypeptide (PACAP) as an emerging target for migraine treatment. PACAP exists as two bioactive forms: a 27-amino acid peptide (PACAP27) and a 38-amino acid form (PACAP38), the latter of which is the focus of research in migraine.1 In the nervous system, it acts as a hormone, neurotransmitter, and neuromodulator, and is found in sensory and pa